HELX Performance — Franklin Genomic Advancements ETF
Data updated: 2026-08-27
HELX returned +9.98% year to date and +44.86% over one year to Jun 2026. Annualised returns are +9.89% over 3 years and −4.93% over 5 years. Against its Health Care Equity category average the fund came out behind over three years but ahead over one: $100 invested three years ago grew to $133, against $138 for the category, and to $145 over one year, against $137. Volatility over the past three years was 21.96% a year. In the 12 months to Jun 2026 the fund took in a net $9.8M, and assets reached $27.94M.
HELX Growth of $100
What $100 invested in Franklin Genomic Advancements ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | HELX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $145 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $133 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $78 | $121 |
| Since data start (Feb 2020 – Jun 2026) | $161 | $168 |
HELX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +9.98% |
| 1 year | +44.86% |
| 3 years (annualised) | +9.89% |
| 5 years (annualised) | −4.93% |
HELX Annual Returns
Calendar-year total returns of Franklin Genomic Advancements ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +9.98% |
| 2025 | +25.91% |
| 2024 | −5.07% |
| 2023 | +1.22% |
| 2022 | −37.85% |
| 2021 | +9.68% |
| 2020 (Feb–Dec) | +77.47% |
HELX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.6% | −5.3% | −4.5% | +1.2% | +6.0% | +12.7% | — | — | — | — | — | — |
| 2025 | +6.2% | −4.7% | −8.0% | +0.9% | −5.0% | +7.0% | +0.4% | +7.5% | +3.7% | +13.9% | +8.1% | −4.3% |
| 2024 | −2.2% | +7.8% | +1.9% | −8.2% | +3.2% | +2.1% | +6.1% | −0.9% | −2.7% | −7.0% | +2.7% | −6.4% |
| 2023 | +5.4% | −6.3% | +2.2% | −1.8% | −1.3% | +2.4% | +3.5% | −1.6% | −7.8% | −10.2% | +9.4% | +9.4% |
| 2022 | −19.4% | −3.5% | −1.8% | −11.8% | +2.3% | −3.8% | +10.3% | −9.4% | −7.4% | +4.2% | +3.2% | −5.7% |
| 2021 | +7.9% | −6.0% | −3.7% | +6.7% | −5.5% | +18.6% | +2.6% | +5.7% | −6.9% | +2.0% | −6.4% | −2.6% |
| 2020 | — | −2.4% | −7.5% | +17.1% | +11.7% | +4.2% | +11.1% | +3.7% | −1.2% | +1.5% | +13.1% | +10.4% |
HELX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 21.96%
- 3-year Sharpe ratio: 0.25 (vs 4.5% risk-free rate)
- Best month: +13.87% (Oct 2025)
- Worst month: −10.16% (Oct 2023)
HELX Fund Flows
Monthly money in and out of Franklin Genomic Advancements ETF, from SEC Form N-PORT.
- 12-month net flow: $9.8M
- 12-month gross sales (incl. reinvestments): $9.8M
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $2.0M | $0 | $2.0M |
| May 2026 | $0 | $0 | $0 |
| Apr 2026 | $0 | $0 | $0 |
| Mar 2026 | $0 | $0 | $0 |
| Feb 2026 | $0 | $0 | $0 |
| Jan 2026 | $1.9M | $0 | $1.9M |
| Dec 2025 | $0 | $0 | $0 |
| Nov 2025 | $0 | $0 | $0 |
| Oct 2025 | $1.6M | $0 | $1.6M |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $2.9M | $0 | $2.9M |
| Jul 2025 | $1.4M | $0 | $1.4M |
HELX Assets Under Management
Net assets of Franklin Genomic Advancements ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $27.94M |
| 2026-03-31 | $21.45M |
| 2025-12-31 | $21.77M |
| 2025-09-30 | $17.01M |
| 2025-06-30 | $11.06M |
| 2025-03-31 | $10.79M |
| 2024-12-31 | $13.02M |
| 2024-09-30 | $9.72M |
| 2024-06-30 | $9.51M |
| 2024-03-31 | $9.83M |
| 2023-12-31 | $10.67M |
| 2023-09-30 | $8.51M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.